Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Has Average Target Price of $98.31

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have earned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $98.31.

ARWR has been the topic of a number of analyst reports. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Chardan Capital reiterated a “buy” rating and issued a $115.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Leerink Partners raised their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research report on Wednesday, June 17th. JPMorgan Chase & Co. boosted their price target on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Finally, Morgan Stanley increased their price objective on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $64.19 on Monday. The firm has a market capitalization of $9.04 billion, a P/E ratio of -28.53 and a beta of 1.29. Arrowhead Pharmaceuticals has a 52 week low of $34.61 and a 52 week high of $95.49. The stock has a 50 day moving average price of $80.83 and a two-hundred day moving average price of $75.69. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. During the same quarter in the prior year, the business earned ($1.26) EPS. The firm’s revenue for the quarter was up 171.0% compared to the same quarter last year. Equities analysts forecast that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 11,600 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the transaction, the director owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the transaction, the director owned 31,600 shares of the company’s stock, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. grew its position in shares of Arrowhead Pharmaceuticals by 243.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 201,927 shares of the biotechnology company’s stock valued at $16,459,000 after acquiring an additional 143,192 shares during the period. Siren L.L.C. raised its holdings in shares of Arrowhead Pharmaceuticals by 7.7% in the 1st quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock worth $101,290,000 after purchasing an additional 115,000 shares during the period. Squarepoint Ops LLC bought a new position in Arrowhead Pharmaceuticals during the second quarter valued at $20,859,000. Elevation Point Wealth Partners LLC bought a new position in Arrowhead Pharmaceuticals during the first quarter valued at $751,000. Finally, Empowered Funds LLC increased its position in Arrowhead Pharmaceuticals by 661.6% in the first quarter. Empowered Funds LLC now owns 137,220 shares of the biotechnology company’s stock worth $8,604,000 after buying an additional 119,202 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.